STAT

How one company thinks unraveling cough can provide a new way to treat pain

Source: George Marks/Retrofile/Getty Images

It was a cold night in Boston, and the valets were taking forever, so two neurobiologists got to talking about a fitting topic: pain.

Bruce Bean and Dr. Clifford Woolf, both professors at Harvard Medical School, were vexed by the struggle to come up with viable new painkillers. The therapies of yesteryear dimmed pain but could cause numbness and immobility. Opiates could be addictive. There have been new kinds of painkillers, but they have come with safety and efficacy issues of their own.

“We just started talking about whether there was some novel way that we could selectively target pain-sensing neurons,” Bean said, and the two parted ways with a mutual challenge.

That conversation, between shivering scientists outside a now-defunct French restaurant, set in motion a decade-long quest to build a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks